These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 26450707)

  • 41. Topical and light-based treatments for basal cell carcinoma.
    Robinson JK; Hernandez C; Anderson ER; Nickoloff B
    Semin Cutan Med Surg; 2003 Sep; 22(3):171-6. PubMed ID: 14649584
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of imiquimod as compared with surgery on the cancerization field in basal cell carcinoma.
    Graells J; Ojeda RM; García-Cruz A
    Actas Dermosifiliogr; 2014; 105(1):53-9. PubMed ID: 24139468
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunomodulation by imiquimod in patients with high-risk primary melanoma.
    Narayan R; Nguyen H; Bentow JJ; Moy L; Lee DK; Greger S; Haskell J; Vanchinathan V; Chang PL; Tsui S; Konishi T; Comin-Anduix B; Dauphine C; Vargas HI; Economou JS; Ribas A; Bruhn KW; Craft N
    J Invest Dermatol; 2012 Jan; 132(1):163-9. PubMed ID: 21850019
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Has imiquimod 5% cream a role in the management of recurrent basal cell carcinoma?
    RUIZ-VILLAVERDE R; SANCHEZ-CANO D; BURKHARDT-PEREZ P; SINTES RN
    Eur J Dermatol; 2009; 19(5):481-3. PubMed ID: 19527989
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nonsyndromic multiple basal cell carcinomas successfully treated with imiquimod 5% cream.
    Kocabaş E; Ermertcan AT; Bilaç C; Bilaç DB; Temiz P
    Cutan Ocul Toxicol; 2010 Dec; 29(4):300-2. PubMed ID: 20684662
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe.
    Gollnick H; Barona CG; Frank RG; Ruzicka T; Megahed M; Maus J; Munzel U
    Eur J Dermatol; 2008; 18(6):677-82. PubMed ID: 18955210
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of infiltrating basal cell carcinoma with the combination of intralesional IFNalpha-2b and topical imiquimod 5% cream.
    Turan A; Saricaoglu H; Baskan EB; Toker SC; Tunali S
    Int J Dermatol; 2009 Feb; 48(2):214-5. PubMed ID: 19200213
    [No Abstract]   [Full Text] [Related]  

  • 48. The role of topical immune response modifiers in skin cancer.
    Woodmansee C; Pillow J; Skinner RB
    Drugs; 2006; 66(13):1657-64. PubMed ID: 16978032
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Letter: Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular basal cell carcinomas before Mohs micrographic surgery: a randomized, double-blind, vehicle-controlled study.
    Moehrle M; Breuninger H; Schippert W; Häfner HM
    Dermatol Surg; 2010 Mar; 36(3):428-30. PubMed ID: 20402949
    [No Abstract]   [Full Text] [Related]  

  • 50. Eruptive epidermoid cysts resulting from treatment with imiquimod.
    Marty CL; Randle HW; Walsh JS
    Dermatol Surg; 2005 Jul; 31(7 Pt 1):780-2; discussion 782-3. PubMed ID: 16029707
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Eruptive epidermoid cysts during topical imiquimod treatment].
    Dillies AS; Gras-Champel V; Fraitag-Spinner S; Al Saïf F; Carmi E
    Ann Dermatol Venereol; 2017 Mar; 144(3):212-215. PubMed ID: 27765414
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Peculiar clinical and dermoscopic remission pattern following imiquimod therapy of basal cell carcinoma in seborrhoeic areas of the face.
    Diluvio L; Campione E; Paternò EJ; Orlandi A; Terrinoni A; Chimenti S
    J Dermatolog Treat; 2009; 20(2):124-9. PubMed ID: 18991155
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 'Rub on' treatment for basal-cell carcinoma.
    Kerr C
    Lancet Oncol; 2002 Apr; 3(4):201. PubMed ID: 12067676
    [No Abstract]   [Full Text] [Related]  

  • 54. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies.
    Geisse J; Caro I; Lindholm J; Golitz L; Stampone P; Owens M
    J Am Acad Dermatol; 2004 May; 50(5):722-33. PubMed ID: 15097956
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma.
    Gowda S; Tillman DK; Fitzpatrick JE; Gaspari AA; Goldenberg G
    J Cutan Pathol; 2009 Aug; 36(8):878-81. PubMed ID: 19586497
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
    Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
    J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of 5% imiquimod cream in treating patients with multiple superficial basal cell carcinomas.
    Marks R; Owens M; Walters SA;
    Arch Dermatol; 2004 Oct; 140(10):1284-5. PubMed ID: 15492200
    [No Abstract]   [Full Text] [Related]  

  • 58. [Topical immunomodulator against skin cancer. Does the cream replace the knife? (interview by Dr. Judith Neumaier)].
    Hauschild A
    MMW Fortschr Med; 2005 Sep; 147(37):21. PubMed ID: 16193872
    [No Abstract]   [Full Text] [Related]  

  • 59. Topical treatment strategies for non-melanoma skin cancer and precursor lesions.
    McGillis ST; Fein H
    Semin Cutan Med Surg; 2004 Sep; 23(3):174-83. PubMed ID: 15584683
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Letter: Changes in dermoscopic features in superficial basal cell carcinomas treated with imiquimod.
    Micantonio T; Fargnoli MC; Piccolo D; Peris K
    Dermatol Surg; 2007 Nov; 33(11):1403-5. PubMed ID: 17958603
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.